Holzkirchen, June 4, 2014 - Sandoz, the generic pharmaceuticals division of Novartis, today announced the launch in several European countries of generic escitalopram, an affordable and high-quality version of reference product Cipralex®.
The Sandoz product, which is available in all strengths approved for the reference product (5mg, 10mg, 15mg and 20mg), was launched initially in countries including Belgium, France, Germany, Italy, Sweden and Switzerland.
Nick Haggar, Head of Sandoz Western Europe, Middle East and Africa, said: “Sandoz is already a regional leader in the segment of generic CNS (central nervous system) therapies. This launch further strengthens that position and drives access to affordable high-quality versions of critical medicines.”
The Western European market for (branded) escitalopram is currently valued at approximately USD 600 million (IMS, 2013).
1Cipralex® is a registered trademark of Lundbeck.
Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the generic pharmaceutical sector. Sandoz employs over 26,500 employees and its products are available in more than 160 countries, offering a broad range of high-quality, affordable products that are no longer protected by patents. With USD 9.2 billion in sales in 2013, Sandoz has a portfolio of approximately 1,100 molecules, and holds the #1 position globally in biosimilars as well as in generic injectables, ophthalmics, dermatology and antibiotics, complemented by leading positions in the cardiovascular, metabolism, central nervous system, pain, gastrointestinal, respiratory, and hormonal therapeutic areas. Sandoz develops, produces, and markets these medicines, as well as active pharmaceutical and biotechnological substances. Nearly half of Sandoz's portfolio is in differentiated products, which are defined as products that are more difficult to scientifically develop and manufacture than standard generics.
In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has benefitted from strong growth of its acquisitions, which include Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US).